Skip to main content

Table 2 Outcomes measures

From: Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations

Study

Health outcomes

Measurement of effectiveness

WTPa

Alberts et al. [36]

QALY

Cost saving

47,438 €/QALY

Barone et al. [34]

QALY

ICER

60,000 €/QALY

Barzi et al. [17]

LYG

ICER

47,438 €/LYG

Behl et al. [33]

LYG

ICER

98,876 €/QALY

Blank et al. [31]

QALY

ICER

47,438–98,876 €/QALY (USA); 23,342–35,014 €/QALY (UK)

Dinh et al. [27]

QALY/LYG

ICER

47,438 €/QALY

Gallego et al. [18]

QALY

ICER

98,876 €/QALY

Gausachs et al. [19]

Incremental increase in N. of cases detected

ICER

NR

Gould-Suarez et al. [20]

Incremental increase in N. of cases detected

ICER

NR

Gudgeon et al. [21]

Incremental increase in N. of cases detected

ICER

NR

Ladabaum et al. [28]

LYG

ICER

47,438 €/LYG

Leenen et al. [22]

LYG

ICER

40,000 €/LYG

Severin et al. [23]

LYG

ICER

50,000 €/LYG

Sie et al. [24]

LYG

ICER

80,000 €/LYG

Snowsill et al. [27]

QALY

ICER

23,342 €/QALY

Snowsill et al. [25]

QALY

ICER

NR

Vijayaraghavan et al. [32]

LYG

ICER

NR

Wang et al. [29]

QALY

ICER

NR

Wang et al. [30]

LYG

ICER

NR

Westwood et al. [35]

QALY

ICER

19,841 €/QALY

  1. QALY quality-adjusted life year, WTP willingness-to-pay, ICER incremental cost-effectiveness ratio, LYG life years gained, USA United States, UK United Kingdom, NR not reported
  2. aCurrencies transformed into 2016 Euro values via purchasing power parities (PPPs)